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OBJECTIVE: MicroRNAs are noncoding RNA molecules involved in the development and progression of
tumors. We have found that miRNA-100 is underexpressed in metastatic prostate cancer compared to
localized disease. Conversely higher levels of miR-100 are related to biochemical recurrence after surgery. This
suggests that miR-100 may be a context-dependent miRNA, acting as oncogene or tumor suppressor miRNA.
Our aim is to demonstrate the role of miR-100 in the control of predicted target genes in prostate cancer cell
lines.
METHODS: Cell lines DU145 and PC3 were transfected with miR-100, antimiR-100 and after 24 h and 48 h of
exposure, qRT-PCR and western blot were performed for mTOR, FGFR3, THAP2, SMARCA5 and BAZ2A.
RESULTS: There was reduction in mTOR (p= 0.025), THAP2 (p= 0.038), SMARCA5 (p= 0.001) and BAZ2A
(p=0.006) mRNA expression in DU145 cells after exposure to miR-100. In PC3 cells, mTOR expression was
decreased by miR-100 (p=0.01). There was a reduction in the expression levels of proteins encoded by studied
genes, ranging from 34% to 69%.
CONCLUSIONS: We demonstrate that miR-100 is a context-dependent miRNA controlling BAZ2, mTOR, FGFR3,
SMARCA5 and THAP2 that might be involved in PC progression. The elucidation of the roles of miRNAs in
tumors is important because they can be used as therapeutic targets in the future.
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& INTRODUCTION
MicroRNAs (miRNAs) are small noncoding RNA mole-
cules that are involved in many cellular processes, and some
have recently been correlated with the development and
progression of different tumors (1). We previously found
that there is a reduction in expression of miRNA-100 during
the transition from localized to metastatic prostate cancer
(2). Yet, conversely, men with higher levels of miR-100 were
more likely to suffer biochemical recurrence after radical
prostatectomy (3). This discrepancy suggests that miR-100 is
a context-dependent miRNA, acting sometimes as oncogene
(oncomiR) and sometimes as tumor suppressor miRNA
(tsmiR). Many genes that are predicted as targets of miR-100
have important roles in cell proliferation, survival and
chromosome stability (http://atlasgeneticsoncology.org/
Genes/MIR100ID51447ch11q24.html). The aim of this study
was to determine the role of miR-100 in the control of these
genes in prostate cancer cell lines.
& METHODS
The prostate cancer cell lines DU145 and PC3 were
maintained in McCoy’s medium with 20% FBS and 1%
antibiotic/antimycotic solution (Sigma Co, St. Louis, MO,
USA) at 37 C˚ in an atmosphere containing 5% CO2. Cells
were grown in 24-well plates, with 5.06104 cells seeded into
each well. Transfections were carried out in Opti-MEM I
with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA),
diluted 1:100 according to the manufacturer’s protocol.
Synthetic miR-100 (catalog number AM17100), antimiR-100
(catalog number AM17000) and their respective scrambled
controls, control miR (ctrl miR; catalog number AM17110)
and control antimiR (ctrl amiR; catalog number AM17010)
were purchased from Ambion (Austin, TX, USA). Negative
controls and miRs were each used at 50 nM.
Total RNA for quantitative PCR was isolated with the
Ambion mirVana kit (Austin, TX, USA) as recommended by
the manufacturer. Quantitative PCR of mTOR, FGFR3,
THAP2, SMARCA5 and BAZ2A was performed with
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TaqMan assays from Applied Biosystems (Foster City, CA,
USA) using 2 mg RNA that was reverse transcribed using
random primers and MultiScribe reverse transcriptase
(Applied Biosystems, Foster City, CA, USA). After reverse
transcription, all samples were subjected to DNaseI
(Invitrogen) treatment to remove contaminating genomic
DNA. All samples were amplified in a 7500 fast real-time
PCR system (Applied Biosystems, Foster City, CA, USA)
and subjected to the comparative DDCt method by using
human ß2 microglobulin as the internal standard. To
calculate the difference in expression under different
conditions, we used the following equations: DDCt =DCt
Pre-miR – DCt Pre-miR negative control and DDCt =DCt
anti-miR – DCt anti-miR negative control. All results were
normalized to the control as 100%. The data shown are
representative of three independent experiments. Statistical
significance was calculated by two-tailed Student’s t-test,
and p,0.05 was considered significant. Statistical analyses
were performed using GraphPad Prism version 5.
For Wester blotting, DU145 and PC3 cells (2.56105 cells/
well) were transfected with 50 nM of pre-miR 100 or its
control. After 48 h, the cells were resuspended and lysed in
their wells using RIPA buffer and protease inhibitor
(Millipore, Billerica, MA, USA). Protein concentrations were
established using the Pierce 660 nm Protein Assay (Thermo
Scientific). Cell lysate samples containing 30 mg of protein
were electrophoresed in a 12% SDS-polyacrylamide gel. After
electrophoresis, the proteins were transferred to a PVDF
Immobilon-P membrane (Millipore, Billerica, MA, USA). The
membrane was blocked in Tris-buffered saline (TBS) contain-
ing 1% BSA (bovine serum albumin) (Sigma, St. Louis, MO,
USA) and 1% Tween-20 for 15 sec at room temperature. The
membranes were then incubated with primary antibody for
20 min in the SNAP i.d. protein detection system (Millipore)
according to the manufacturer’s instructions. The primary
antibodies are described in table 1. b-actin was used as a
control. The secondary antibody was used at a dilution of
1:5000 with an incubation time of 20 min (Millipore) in the
same instrument. The protein expression analysis was
performed with Alliance 4.7 equipment (Uvitec,
Cambridge, UK) using the Alliance 16.06 software.
& RESULTS
DU145 cells exposed to Pre-miR-100 showed a significant
reduction in the mRNA expression of mTOR (62.3%,
p= 0.025), THAP2 (24.6%, p= 0.038), SMARCA5 (65.6%,
p= 0.0012) and BAZ2A (58.7%, p= 0.006). FGFR3 expression
was reduced by 24%, but this change was not statistically
significant (p= 0.194). Exposure to anti-miR-100 stimulated
an increase in the expression of all of the genes tested, but
the change was significant for only BAZ2A, which exhibited
an increase of 68.5% (p= 0.0147) (Figure 1).
PC3 cells exhibited a significant reduction in the expres-
sion of mTOR after exposure to Pre-miR-100 (82.2%,
p= 0.0103). The other four genes also showed reductions in
expression, but this difference was not statistically signifi-
cant. When exposed to anti-miR-100, all genes except
SMARCA5 exhibited increased expression, but with no
statistical significance (Figure 2).
Wester blot analysis showed that miR-100 negatively
regulates mTOR, THAP2, SMARCA5 and BAZ2A and also
causes a significant reduction in the protein expression of
FGFR3, as shown in Figure 3. While miR-100 had no effect
on the mRNA levels of these genes in PC3 cells, the
expression of the corresponding proteins was significantly
reduced after exposure to the miRNA (Figure 4).
& DISCUSSION
Hundreds of microRNA target genes have been predicted
by bioinformatics methods, but few have been substantiated
by experimental assays. We have previously shown that
miR-100 could be a context dependent miRNA that is
differentially expressed during prostate cancer progression
(2,3). In this study, we were able to show that miR-100
functions differently in two different prostate cancer cell
lines and targets genes that can be classified as oncogenes or
tumor suppressor genes.
The mTOR/PI3K/AKT pathway is related to many
cellular processes, including cell proliferation and survival,
and the deregulation of this pathway has been correlated
with the progression of different tumors including prostate
(4). The PI3Ks are enzymes involved in the phosphorylation
of membrane inositol lipids to mediate cellular signal
transduction (5). Receptor tyrosine kinases (RTKs) and
some non-RTKs can activate PI3K, generating the second
messenger PIP3 (phosphatidylinositol (3,4,5)-triphosphate).
This activation drives a conformational change in AKT/
PKB, resulting in the activation of both the mTORC1 and
mTORC2 complexes and thus inducing cell survival, cell
cycle progression and proliferation, cell migration, and
angiogenesis. AKT is negatively regulated by the tumor
suppressor PTEN (phosphatase and tensin homolog deleted
on chromosome 10), which dephosphorylates PIP3. PTEN is
often deleted in prostate cancer, and its deletion is
associated with a high Gleason score (6) and castration-
resistance status (7). We believe that the underexpression of
miR-100 in metastatic prostate cancer and prostate cancer
cell lines could act as a tsmiR, contributing to the
upregulation of the mTOR pathway.
However, we have also shown that SMARCA5 and BAZ2A
are also targets of miR-100. SMARCA5 is a member of the
SWI/SNF protein family, which is involved in cell cycle
regulation and signal transduction, facilitating the mainte-
nance of heterochromatin by directing histone deacetylation
during the cell cycle. The proper function of these SWI/SNF-
like factors is required for accurate chromosome segregation
during mitosis, preventing genomic instability and guarantee-
ing the efficient transmission of epigenetic information (8).
Recently, SMARCA5 has been identified as a target of another
member of the miR-100 family, miR-99a that is overexpressed
in synovial sarcoma (9), confirming our findings.
BAZ2A, also known as TIP5 and WALp3, functions together
with the SWI/SNF family member SNF2h to form the NoRC
(nucleolar remodeling complex). This complex induces nucleo-
some sliding, which is important for transcription regulation
Table 1 - Antibodies used for quantification of protein
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Figure 1 - The expression of the mTOR, FGFR3, THAP2, SMARCA5 and BAZ2A genes in DU145 prostate cancer cells, as evaluated by qRT-
PCR, after exposure to miR-100 and anti-miR-100.
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Figure 2 - The expression of the mTOR, FGFR3, THAP2, SMARCA5 and BAZ2A genes in PC3 prostate cancer cells, as evaluated by qRT-
PCR, after exposure to miR-100 and anti-miR-100.
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(10). We believe that the overexpression of miR-100 in localized
prostate cancer, which is related to biochemical recurrence,
promotes the downregulation of both transcription control-
related genes, leading to genetic instability, a well-known
prognostic factor in prostate cancer (11,12). Although the
biological roles of cellular THAP proteins remain unknown,
some studies have shown that they are important in cell
proliferation and cell cycle control. Bessie`re et al. recently
showed that THAP1 is an endogenous physiological regulator
of endothelial cell proliferation and G1/S cell cycle progression
that modulates the expression of several pRb/E2F cell cycle
target gene (13). We have confirmed the role of miR-100 as an
oncomiR in localized prostate cancer, showing that it down-
regulates THAP2 (THAP domain containing apoptosis asso-
ciated protein 2), thus increasing cell proliferation through the
pRb pathway.
Figure 3 - mTOR, FGFR3, THAP2, SMARCA5 and BAZ2A protein expression in DU145 prostate cancer cells, as evaluated by wester
blotting, after exposure to miR-100.
Figure 4 - mTOR, FGFR3, THAP2, SMARCA5 and BAZ2A protein expression in PC3 prostate cancer cells, as evaluated by wester blotting,
after exposure to miR-100.
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These results affirm that miR-100 is a context-dependent
miRNA in prostate cancer that influences the fate of tumor
cells; miR-100 sometimes acts as an oncomiR by impairing
cell cycle control and promoting genomic instability by
downregulating SMARCA5, BAZ2A and THAP2, while in
other contexts it acts as a tsmiR, cooperating with other
factors to downregulate the mTOR pathway.
The practical importance of our data is related to the
possibility of using this miRNA as a targeted drug to treat
neoplasias. Each miRNA should be studied in detail
because miRNAs may have many target genes, and their
context-dependence might produce broad effects that could
be harmful to patients.
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